A 28-year FMCG career. A conviction that Western longevity science doesn't fit Indian bodies. India's first longevity clinic — backed by Nikhil Kamath, Accel and Manipal.
Rishi Pardal left the CEO chair of United Breweries in 2023 and built BioPeak — India's first full-stack precision longevity platform — on a single insight: every ageing clock, biomarker norm, and supplement protocol being sold to India was calibrated for someone else's body. 130+ biomarkers, IISc's BHARAT Study, Modern Mayr Medicine, and Nikhil Kamath's repeat investment later, BioPeak is the deepest clinical bet ever placed on the Indian healthspan.
Rishi Pardal & Shiva Subramanian
Co-Founders · BioPeak
The Problem With Borrowing Western Longevity Science
Rishi Pardal had spent 28 years watching India misapply frameworks designed for someone else. At Hindustan Unilever, Avery Dennison, Marico Bangladesh, and finally United Breweries — where he served as CEO from 2020 to 2023 — he had seen how deeply context-specific the right solution needed to be. What worked in Europe or America often needed to be rebuilt almost entirely for the Indian consumer, the Indian market, and the Indian body.
The longevity industry was committing the same error, and at far higher stakes. The ageing clocks, the biomarker reference ranges, the dietary protocols, the supplementation regimens being imported into India's premium wellness market were all calibrated to Western populations — to European and American diets, genetics, disease histories, and environmental exposures. An Indian body that consumed turmeric daily, ate predominantly vegetarian, lived in a high-pollution urban environment, and carried a genetic susceptibility to metabolic disease was being evaluated against a reference point that did not describe it.
Pardal co-founded BioPeak in June 2024 with Shiva Subramanian — a bioengineering specialist with deep expertise in precision performance systems — to build the alternative: a full-stack longevity platform that was built on Indian data, staffed by Indian scientists, designed for Indian disease patterns, and delivered through India's first dedicated longevity clinic.
Nikhil Kamath, Accel, Manipal Group and the Clinical Build
The investor lineup that backed BioPeak was itself a statement about where India's most sophisticated capital was pointing. Nikhil Kamath — Zerodha co-founder, India's most visible young billionaire, and a founder who has spoken publicly about his own interest in longevity science — invested $1.43M in August 2024, months before BioPeak had a clinic or a product. It was a thesis investment in Rishi Pardal's ability to build something clinically serious.
The seed round that followed in mid-2025 brought in two more validation-grade names. Prashanth Prakash, the founding partner of Accel India who backed Flipkart and Swiggy, joined as investor and mentor. He is also the Founding Patron of Longevity India, IISc's research platform — making his investment in BioPeak an extension of his institutional conviction about ageing science in India. Claypond Capital — the family office of Ranjan Pai, chairman of the Manipal Group — brought the credibility of India's largest private healthcare and education empire.
The clinic that opened in Bengaluru in March 2025 delivered on the thesis. 130+ biomarker blood panels. DEXA scans. VO₂ max testing. Whole-exome functional genomics. Gut microbiome mapping. Salivary cortisol rhythm analysis. Organic acid profiling. Non-invasive imaging across MRI, CT, DXA, and ECHO. More than six hours of consultations with a multidisciplinary team. The Longevity Hexacode — BioPeak's proprietary six-layer system — translated all of it into a personalised health blueprint. It was unlike anything else available in India.
BHARAT Study, Modern Mayr and the Long Game
The most consequential thing BioPeak has built is not the clinic — it is the data layer underneath it. Chief Scientific Officer Dr. Deepak Kumar Saini is an IISc professor who leads research on cellular signalling, ageing, and inflammation, and whose team is anchoring the BHARAT Study (Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions) — India's first comprehensive ageing database. BioPeak is the BHARAT Study's clinical partner and a Tier 1 sponsor of IISc's RISE 2025 conference. Every client who walks through BioPeak's doors contributes data to the effort to understand how Indians actually age, organ by organ, in the context of their own genetics and environment.
The Modern Mayr Medicine partnership — announced in October 2025 with Prof. Dr. Harald Stossier, a global authority on gut health and metabolic restoration — added 150 years of European clinical heritage to the platform. The BioPeak–Modern Mayr programme, scheduled for 2026, will bring Mayr diagnostics and protocols adapted to Indian ethnicity and lifestyle. Advisory board members Dr. Satchin Panda (Salk Institute, circadian medicine expert) and Irina Sharma (Modern Mayr practitioner) complete a scientific bench that is genuinely world-class.
Nikhil Kamath's second investment in January 2026 — $2.7M — funds the second Bengaluru clinic, deeper AI tools, and the IISc research programme. Pardal's framing remains deliberately measured: "Longevity in India needs to be built carefully — with strong clinical foundations and a long-term view." In a category full of supplement brands and wellness apps, BioPeak is choosing to be the institution.
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways. Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan. And it has to be built on Indian data — not borrowed from the West."
— Rishi Pardal, Co-Founder & CEO, BioPeak (June 2025)
Company Timeline
- Jun 2024
Rishi Pardal — ex-CEO United Breweries, ex-Business Head HUL, ex-VP Avery Dennison — co-founds BioPeak Wellness Private Limited in Bengaluru with Shiva Subramanian (ex-Phitons Bioengineering, University of Nottingham). The founding thesis: Western longevity science does not apply to Indian bodies, Indian disease patterns, or Indian diets. BioPeak will build the first longevity platform calibrated entirely to Indian biology.
- Aug 2024
First funding: $1.43M from Nikhil Kamath's NKSquared. Kamath — Zerodha co-founder, India's most visible young billionaire — invests as an individual believer in the longevity thesis. Product development begins. Chief Scientific Officer Dr. Deepak Kumar Saini, IISc professor of Developmental Biology and Genetics, joins the leadership team. Deepak Saini also serves as Chief Scientific Officer at Longevity India (IISc).
- Jun 2025
Seed round closed: $3.5M (₹29 crore) from Accel India founding partner Prashanth Prakash, Claypond Capital (family office of Manipal Group chairman Ranjan Pai), and NKSquared. Prashanth Prakash, Founding Patron of Longevity India, also becomes a mentor to BioPeak. Funds deployed toward clinic build-out, AI platform development, and clinical programme design.
- Mar 2025
India's first dedicated longevity clinic launches in Bengaluru. The clinic opens as BioPeak's first physical manifestation — offering 130+ biomarker blood panels, DEXA, VO₂ max, whole-exome genomics, microbiome mapping, and 6+ hour multidisciplinary consultations. The Longevity Hexacode — BioPeak's proprietary six-layer diagnostic and intervention system — goes live for clients.
- Aug 2025
India's first longevity clinic formally announced to media. BioPeak becomes a Tier 1 sponsor and Longevity Luminaries partner of IISc's RISE 2025 conference — Longevity India's flagship annual event. The BHARAT Study partnership deepens: BioPeak's clinical data and Indian client cohort contributes to India's first comprehensive ageing biomarker database. Exclusive longevity partner at Rainmatter's peakst8 Festival.
- Oct 2025
BioPeak announces landmark partnership with Austria's Modern Mayr Medicine — bringing 150 years of European preventive health wisdom (gut health, detoxification, metabolic restoration) to India via culturally adapted programmes. Prof. Dr. Harald Stossier and Irina Sharma join BioPeak's advisory board. A joint BioPeak–Modern Mayr programme is slated for 2026. BioPeak is now described as India's first full-stack precision health and longevity platform.
- Jan 2026
$2.7M follow-on round from NKSquared — Nikhil Kamath's second investment in BioPeak. Total raised: $6.2M. Proceeds: second Bengaluru clinic (opening within weeks), enhanced AI diagnostics, research initiatives with IISc, and expansion of clinical programmes. Rishi Pardal in The Economic Times: 'Longevity in India needs to be built carefully; with strong clinical foundations and a long-term view.' The second clinic is BioPeak's proof of the model.
Frequently Asked Questions
What is the Longevity Hexacode and how does it work?
The Longevity Hexacode is BioPeak's proprietary six-layer diagnostic and intervention framework — the core intellectual property of the platform. It integrates six data streams: molecular diagnostics (multiomics), advanced imaging (MRI, CT, DXA, ECHO), tissue-level screenings (toxin, mineral, oxidative stress), AI analytics, wearable data, and specialist clinical interpretation. Rather than a single test or a report, the Hexacode produces a personalised health blueprint that identifies biological dysfunction before it becomes disease — and maps it to actionable intervention protocols in nutrition, sleep, stress, movement, and lifestyle medicine. It is what differentiates BioPeak from any diagnostic lab or wellness app.
Who is Rishi Pardal and why did he leave corporate India to build a longevity startup?
Rishi Pardal spent 28 years in FMCG and consumer goods — Brand Manager at HUL (1998–2003), Business Head and GM at Hindustan Unilever (2003–2010), MD at Marico Bangladesh, VP & MD South Asia at Avery Dennison, VP & GM Asia Pacific at Avery Dennison, and CEO & MD of United Breweries Ltd. / Kingfisher (2020–2023). He is also an active angel investor with 18 portfolio companies. He left UBL in 2023 and founded BioPeak in June 2024 — drawn by the intersection of a problem he identified deeply (longevity science calibrated to Indian biology) and a market timing he believed was arriving: molecular diagnostics, AI, and imaging had all crossed a threshold where a genuinely different standard of preventive care became possible.
What makes BioPeak's scientific advisory board significant?
BioPeak's scientific bench is genuinely world-class for an early-stage Indian startup. Chief Scientific Officer Dr. Deepak Kumar Saini is an IISc professor specialising in cellular signalling and ageing who leads the BHARAT Study — India's first comprehensive ageing biomarker database. Dr. Satchin Panda is a globally recognised circadian biology expert from the Salk Institute whose research on time-restricted eating has shaped mainstream health guidance. Prof. Dr. Harald Stossier is the pioneer of Modern Mayr Medicine, a 150-year European tradition in gut health and metabolic restoration. This advisory structure means BioPeak's clinical programmes are shaped by the researchers actively advancing the science — not just applying published guidelines.
What is the BioPeak CXO Programme and who is it for?
The BioPeak CXO Programme is a dedicated longevity strategy for senior executives and leaders. It is designed on the insight that the demands of leadership — chronic stress, travel, high-stakes decisions, irregular sleep — create a specific and measurable biological toll. The programme delivers a full BioPeak diagnostic workup tailored to executive health patterns, then builds a proactive health roadmap that covers metabolic function, cognitive resilience, stress biology (salivary cortisol rhythms), sleep architecture, and physical performance. The goal is to shift health management from reactive — visiting a doctor when sick — to predictive and preventive. BioPeak's data shows that most CXO health issues begin as silent biological dysfunction visible in biomarkers, years before symptoms appear.